On March 13, 2026, Profound Medical Corp. announced that its CAPTAIN trial, which compares the MRI-guided TULSA Procedure to robotic radical prostatectomy, successfully met its primary safety endpoint. The trial demonstrated a statistically significant improvement in preserving erectile function and urinary continence at six months post-treatment. With 211 patients treated, the TULSA Procedure showed that 50% of patients maintained both functions compared to only 24% after robotic surgery. This pivotal trial positions TULSA as a potential standard of care in prostate cancer treatment.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.